You will now be redirected to the GD3 website
Genesis Drug Discovery & Development is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.
Learn more about GD3Chemistry
Antibody-Drug Conjugates
What are Antibody-Drug Conjugates?
Antibody-Drug Conjugates (ADC) are an important new class of biopharmaceutical drugs. ADCs deliver potent anti-cancer agents directly to the target tumor. ADCs combine the targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs.
ADCs comprise a tumor-specific antibody connected via a chemical linker to a biologically active drug or cytotoxic compound. Combining an antibody's exquisite targeting capabilities with potent drug molecules makes these innovative therapeutics highly efficacious without the side effects of traditional chemotherapeutic agents.
Learn more about